Biotechnology company Gilead Sciences Inc. said Tuesday it completed its cash tender offer for shares of Myogen Inc.

Gilead said preliminary results show about 40.1 million shares, or more than 91.3 percent of outstanding stock, were validly tendered and not withdrawn prior to the expiration of the tender offer on Monday.

All shares have been accepted for payment.

In October, Gilead said it planned to buy Westminster, Colo.-based drug company Myogen for $52.50 cash per share, or about $2.5 billion.

Shares of Gilead rose 23 cents to $67.30 during premarket electronic trading on the INET.